1. Home
  2. ZNTL vs ATLO Comparison

ZNTL vs ATLO Comparison

Compare ZNTL & ATLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZNTL
  • ATLO
  • Stock Information
  • Founded
  • ZNTL 2014
  • ATLO 1903
  • Country
  • ZNTL United States
  • ATLO United States
  • Employees
  • ZNTL N/A
  • ATLO N/A
  • Industry
  • ZNTL Biotechnology: Pharmaceutical Preparations
  • ATLO Major Banks
  • Sector
  • ZNTL Health Care
  • ATLO Finance
  • Exchange
  • ZNTL Nasdaq
  • ATLO Nasdaq
  • Market Cap
  • ZNTL 137.9M
  • ATLO 158.4M
  • IPO Year
  • ZNTL 2020
  • ATLO N/A
  • Fundamental
  • Price
  • ZNTL $1.29
  • ATLO $16.80
  • Analyst Decision
  • ZNTL Buy
  • ATLO
  • Analyst Count
  • ZNTL 8
  • ATLO 0
  • Target Price
  • ZNTL $8.53
  • ATLO N/A
  • AVG Volume (30 Days)
  • ZNTL 927.8K
  • ATLO 15.9K
  • Earning Date
  • ZNTL 05-06-2025
  • ATLO 05-07-2025
  • Dividend Yield
  • ZNTL N/A
  • ATLO 4.72%
  • EPS Growth
  • ZNTL N/A
  • ATLO N/A
  • EPS
  • ZNTL N/A
  • ATLO 1.26
  • Revenue
  • ZNTL $67,425,000.00
  • ATLO $55,041,000.00
  • Revenue This Year
  • ZNTL N/A
  • ATLO N/A
  • Revenue Next Year
  • ZNTL N/A
  • ATLO N/A
  • P/E Ratio
  • ZNTL N/A
  • ATLO $13.29
  • Revenue Growth
  • ZNTL N/A
  • ATLO 2.24
  • 52 Week Low
  • ZNTL $1.01
  • ATLO $15.69
  • 52 Week High
  • ZNTL $13.46
  • ATLO $22.03
  • Technical
  • Relative Strength Index (RSI)
  • ZNTL 39.50
  • ATLO 42.80
  • Support Level
  • ZNTL $1.01
  • ATLO $16.36
  • Resistance Level
  • ZNTL $1.32
  • ATLO $16.98
  • Average True Range (ATR)
  • ZNTL 0.14
  • ATLO 0.58
  • MACD
  • ZNTL 0.02
  • ATLO -0.02
  • Stochastic Oscillator
  • ZNTL 37.33
  • ATLO 37.57

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

About ATLO Ames National Corporation

Ames National Corporation is a United States-based bank holding company. Through its subsidiaries, it provides checking, savings and time deposits, cash management services, merchant credit card processing, safe deposit boxes, wire transfers, direct deposit of payroll and social security checks, and automated/video teller machine access. Its loan portfolio comprises commercial, residential & agricultural real estate loans; agricultural & business operating loans & lines of credit; equipment loans; vehicle loans; personal loans; and mortgage loans. Its operations are conducted in central, north central, and south-central Iowa.

Share on Social Networks: